Home

Dorman Followwill

CIK 1717947 · last filed 2025-10-09

Dorman Followwill is a corporate insider who has filed 12 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for SCLXW, was dated Oct 9, 2025. Across all open-market trades the lifetime net is −$6.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $253 across reported positions. 7 SEC filings were submitted jointly with Scilex Holding Co.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$253

Companies

2

Total Filings

12

Lifetime Open-Market Net

-$6.1K

Filer Profile

Reported Address
C/O SORRENTO THERAPEUTICS, INC.
4955 DIRECTOR'S PLACE
SAN DIEGO, CA 92121
Related Filers
Scilex Holding Co — 7 joint filings, latest 2025-10-09
Sorrento Therapeutics, Inc. — 7 joint filings, latest 2021-08-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SCLXW Director 2,300 $0.11 $253 $990 6 2025-10-09
Sorrento Therapeutics, Inc. (SRNE) Delisted Director 2,130 $0.00 $1 -$7.1K 6 2021-08-30

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-10-09 SCLXW Grant (A) — $0 EDGAR
2024-12-17 SCLXW Grant (A) — $0 EDGAR
2024-10-18 SCLXW Buy (P) +1,000 $990 EDGAR
2024-06-26 SCLXW Exer (M) +1,000 $1.4K EDGAR
2024-06-26 SCLXW Grant (A) — $0 EDGAR
2023-01-17 SCLXW Grant (A) — $0 EDGAR
2021-08-30 Sorrento Therapeutics, Inc. (SRNE) Delisted Grant (A) — $0 EDGAR
2021-01-26 Sorrento Therapeutics, Inc. (SRNE) Delisted Mixed — -$7.1K EDGAR
2020-06-15 Sorrento Therapeutics, Inc. (SRNE) Delisted Grant (A) — $0 EDGAR
2019-04-23 Sorrento Therapeutics, Inc. (SRNE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.